Sugi Predict

Sugi Predict / Targets / AMDHD2

AMDHD2

N-acetylglucosamine-6-phosphate deacetylase · Q9Y303 · AMDHD2 on Sugi Atlas →

562 patent compounds predicted against AMDHD2, 459 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12973871 SCHEMBL12973871 0.74 1/20
SCHEMBL25084084 SCHEMBL25084084 0.74 1/20
SCHEMBL4363197 SCHEMBL4363197 0.68 1/20
SCHEMBL4363206 SCHEMBL4363206 0.68 1/20
SCHEMBL14669223 SCHEMBL14669223 0.68 1/20
SCHEMBL20291477 SCHEMBL20291477 0.68 1/20
SCHEMBL20299968 SCHEMBL20299968 0.68 1/20
SCHEMBL20558753 SCHEMBL20558753 0.68 1/20
SCHEMBL20912983 SCHEMBL20912983 0.68 1/20
SCHEMBL25361382 SCHEMBL25361382 0.68 1/20
SCHEMBL29394667 SCHEMBL29394667 0.68 1/20
SCHEMBL29425232 SCHEMBL29425232 0.68 1/20
SCHEMBL20154711 SCHEMBL20154711 0.65 1/20
SCHEMBL30189347 SCHEMBL30189347 0.65 1/20
SCHEMBL187934 SCHEMBL187934 0.64 1/20
SCHEMBL708955 SCHEMBL708955 0.64 1/20
SCHEMBL4308485 SCHEMBL4308485 0.64 1/20
SCHEMBL4997000 SCHEMBL4997000 0.64 1/20
SCHEMBL5001024 SCHEMBL5001024 0.64 1/20
SCHEMBL16710620 SCHEMBL16710620 0.64 1/20

Clinical trials — most relevant to AMDHD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Vorinostat in Children PHASE1/PHASE2COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia PHASE2COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Evaluation of Blood Protein O-GlcNAcylation Levels in Children nanRECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children nanRECRUITING
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Genetic-specific Effects of Fructose on Liver Lipogenesis nanCOMPLETED
A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain nanUNKNOWN
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise nanCOMPLETED
Acute Fatty Acid Intervention Study (AFAST) nanCOMPLETED
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AMDHD2 binder may also engage these)

ProteinNameSimilarity
A7MBC0 — 1.000 A7MBC0 →
Q8JZV7 — 1.000 Q8JZV7 →
Q5BJY6 — 0.995 Q5BJY6 →
Q9VR81 — 0.985 Q9VR81 →
Q6P0U0 — 0.984 Q6P0U0 →
O95396 — 0.970 O95396 →
Q3T094 — 0.970 Q3T094 →
O95571 — 0.969 O95571 →
A6H791 — 0.969 A6H791 →
A5GFZ6 — 0.968 A5GFZ6 →
A2VDS1 — 0.968 A2VDS1 →
Q9DCM0 — 0.968 Q9DCM0 →
Q96FX7 — 0.968 Q96FX7 →
O35098 — 0.966 O35098 →
Q5R824 — 0.966 Q5R824 →
A5GFY8 — 0.966 A5GFY8 →
Q8IW45 — 0.966 Q8IW45 →
O75600 — 0.965 O75600 →
Q62951 — 0.965 Q62951 →
O14531 — 0.964 O14531 →
Q9LDN2 — 0.964 Q9LDN2 →
E1BNQ4 — 0.964 E1BNQ4 →
Q8RZA1 — 0.963 Q8RZA1 →
Q64737 — 0.962 Q64737 →
A3NBG6 — 0.962 A3NBG6 →
Q9I676 — 0.962 Q9I676 →
Q14117 — 0.962 Q14117 →
Q60HD7 — 0.962 Q60HD7 →
Q5RDK5 — 0.962 Q5RDK5 →
UROD Uroporphyrinogen decarboxylase 0.962 landscape →